Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

40.56 +0.41 (+1.02%)
Streaming Delayed Price Updated: 2:17 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
33 34 Next >
Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time
The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to the National Health Service (NHS) to impleme 
Via Benzinga
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook. 
Via InvestorPlace
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
Roche provided an update from its study in lung cancer using an anti-TIGIT drug. 
Via Investor's Business Daily
Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study
Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of t 
Via Benzinga
Why Novartis Stock Spiked Today
A massive share buyback program and an improved outlook powered a mid-single-digit rise in the drugmaker's shares today. 
Via The Motley Fool
Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,  
Via Benzinga
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
Via Benzinga
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
The biotech's focus on innovation could be a boon for shareholders. 
Via The Motley Fool
What's Going On With Sonnet BioTherapeutics Stock Today?
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) shares are trading higher after the company announced that the IND for SB221, the Phase 1b/2a trial of SON-1010 (IL12-FHAB) in combination with Roche... 
Via Benzinga
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. 
Via Investor's Business Daily
Is TTOO Stock Really Worth $5? Or Just 5 Cents?
TTOO stock has been red hot in recent days, but the story of MULN stock should give speculative investors in T2 Biosystems caution. 
Via InvestorPlace
Is AbbVie Still a Good Dividend Stock to Buy?
Find out if AbbVie can overcome sinking sales of its top-selling product. 
Via The Motley Fool
Why Is Aravive Stock Sinking Today?
Aravive Inc (NASDAQ: ARAV) shares plunged after the company's Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary... 
Via Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. 
Via Benzinga
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
Via Benzinga
Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories
Wall Street Journal 
Via Benzinga
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) entered a strategic agreement with Roche Holdings AG (OTC: RHHBY) to  
Via Benzinga
New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss
From Genentech
Via Business Wire
Q2 Earnings Scorecard And Analyst Reports
We now have Q2 results from 38 S&P 500 members. 
Via Talk Markets
Nvidia Invested $50 million into This AI Drug Discovery Biotech
Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from 
Via MarketBeat
Topics Artificial Intelligence
2 Nasdaq Stocks That Could Soar This Week
BridgeBio Pharma and Roivant Sciences could make big moves this week. 
Via The Motley Fool
Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories
Benzinga 
Via Benzinga
Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover
The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed. 
Via Investor's Business Daily
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY) 
Via Benzinga
How Roche Just Cut Top 1% Biotech Stock TG Therapeutics Down A Peg
The companies are rivals in the multiple sclerosis treatment realm with Ocrevus and Briumvi. 
Via Investor's Business Daily
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with... 
Via Benzinga
Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis
From Genentech
Via Business Wire
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal ​Muscular ​Atrophy (SMA)​ Able to Sit, Stand and Walk
From Genentech
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.